RCAG
SRPT icon

Rehmann Capital Advisory Group’s Sarepta Therapeutics SRPT Stock Holding History

Rehmann Capital Advisory Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-69
Closed -$10.5K – 2072
2019
Q2 		$10.5K Sell
69
-7
-9% -$851 ﹤0.01% 1327
2019
Q1 		$9.06K Buy
76
+7
+10% +$900 ﹤0.01% 1362
2018
Q4 		$7.53K Hold
69
– – ﹤0.01% 1144
2018
Q3 		$11.1K Hold
69
– – ﹤0.01% 1319
2018
Q2 		$9.12K Buy
69
+19
+38% +$1.79K ﹤0.01% 1373
2018
Q1 		$4K Buy
+50
New +$3.33K ﹤0.01% 1579

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Rehmann Capital Advisory Group's SRPT Position: Q3 2019 in Review

Rehmann Capital Advisory Group sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 69 shares — an estimated $10.5K sold.

Rehmann Capital Advisory Group first reported a position in SRPT in Q1 2018 and held it in 6 quarters. The position peaked at $11.1K in Q3 2018. 340 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

  • Rehmann Capital Advisory Group reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 69 Sarepta Therapeutics shares in Q3 2019, an estimated $10.5K.
  • Rehmann Capital Advisory Group first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 6 quarters.
  • Rehmann Capital Advisory Group's Sarepta Therapeutics position peaked at $11.1K in Q3 2018.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.